Peiwen Li1, Bin Ma2, Shulei Gong1, Xinyu Zhang1, Wenya Li3. 1. Department of Thoracic Surgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Shenyang, 110001, People's Republic of China. 2. Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No. 44 Xiaoheyan Road, Dadong, Shenyang, 110042, Liaoning, People's Republic of China. 3. Department of Thoracic Surgery, The First Hospital of China Medical University, No. 155 North Nanjing Street, Shenyang, 110001, People's Republic of China. saint5288@hotmail.com.
Abstract
BACKGROUND: Endoscopic sleeve gastroplasty (ESG) is a minimally invasive, effective, and safe technique for weight loss intervention. Since a relatively small number of cases were present in previous studies, this study aimed to elucidate the efficacy and safety of ESG. METHODS: Relevant publications were identified through searching PubMed, EMBASE, Cochrane, and Web of Science before March 1, 2019. The percentage of total body weight loss (%TBWL), percentage of excess weight loss (%EWL), and the adverse event rate in each follow-up session were extracted, pooled, and analyzed. Forest plots were graphed based on random effects models. RESULTS: A total of 1542 patients from nine studies were eligible for analysis. The pooled results of %TBWL at 1, 3, 6, and 12 months were 8.78% (p = 0.000), 11.85% (p = 0.000), 14.47% (p = 0.024), and 16.09% (p = 0.063), respectively. The pooled results of %EWL at 1, 3, 6, and 12 months were 31.16% (p = 0.000), 43.61% (p = 0.000), 53.14% (p = 0.000), and 59.08% (p = 0.015), respectively. Finally, the pooled rate of mild adverse events was 72% (p < 0.01), and the pooled estimate of severe adverse events was only 1% (p = 0.08). CONCLUSION: Although the conventional surgical sleeve gastrectomy is the gold standard for bariatric surgery, ESG could be a promising minimally invasive alternative for treating obesity with satisfactory efficacy and low risk.
BACKGROUND: Endoscopic sleeve gastroplasty (ESG) is a minimally invasive, effective, and safe technique for weight loss intervention. Since a relatively small number of cases were present in previous studies, this study aimed to elucidate the efficacy and safety of ESG. METHODS: Relevant publications were identified through searching PubMed, EMBASE, Cochrane, and Web of Science before March 1, 2019. The percentage of total body weight loss (%TBWL), percentage of excess weight loss (%EWL), and the adverse event rate in each follow-up session were extracted, pooled, and analyzed. Forest plots were graphed based on random effects models. RESULTS: A total of 1542 patients from nine studies were eligible for analysis. The pooled results of %TBWL at 1, 3, 6, and 12 months were 8.78% (p = 0.000), 11.85% (p = 0.000), 14.47% (p = 0.024), and 16.09% (p = 0.063), respectively. The pooled results of %EWL at 1, 3, 6, and 12 months were 31.16% (p = 0.000), 43.61% (p = 0.000), 53.14% (p = 0.000), and 59.08% (p = 0.015), respectively. Finally, the pooled rate of mild adverse events was 72% (p < 0.01), and the pooled estimate of severe adverse events was only 1% (p = 0.08). CONCLUSION: Although the conventional surgical sleeve gastrectomy is the gold standard for bariatric surgery, ESG could be a promising minimally invasive alternative for treating obesity with satisfactory efficacy and low risk.
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Gontrand Lopez-Nava; Manoel P Galvão; Immacula da Bautista-Castaño; Amaya Jimenez; Teresa De Grado; Juan Pedro Fernandez-Corbelle Journal: Endoscopy Date: 2014-11-07 Impact factor: 10.093
Authors: Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez Journal: Obes Surg Date: 2008-05-06 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Andres Acosta; Michael Camilleri; Manpreet S Mundi; Elizabeth Rajan; Mark D Topazian; Christopher J Gostout Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: Shailendra Singh; Diogo Turiani Hourneaux de Moura; Ahmad Khan; Mohammad Bilal; Michele B Ryan; Christopher C Thompson Journal: Surg Obes Relat Dis Date: 2019-12-10 Impact factor: 4.734
Authors: Avik Sarkar; Augustine Tawadros; Iman Andalib; Haroon M Shahid; Amy Tyberg; Resheed Alkhiari; Monica Gaidhane; Prashant Kedia; Elizabeth S John; Bryce Bushe; Guadalupe Ma Martinez; Felipe Zamarripa; Mine C Carames; Juan C Carames; Fernando Casarodriguez; Vincenzo Bove; Guido Costamagna; Ivo Boskoski; Michel Kahaleh Journal: Ther Adv Gastrointest Endosc Date: 2022-06-07
Authors: Prudence Carr; Tim Keighley; Peter Petocz; Michelle Blumfield; Graeme G Rich; Felicity Cohen; Asha Soni; Isabella R Maimone; Flavia Fayet-Moore; Elizabeth Isenring; Skye Marshall Journal: BMC Prim Care Date: 2022-02-05
Authors: Maria V Matteo; Vincenzo Bove; Valerio Pontecorvi; Martina De Siena; Gabriele Ciasca; Massimiliano Papi; Giulia Giannetti; Giorgio Carlino; Marco Raffaelli; Guido Costamagna; Ivo Boškoski Journal: Obes Surg Date: 2022-08-02 Impact factor: 3.479